Laureate Pharma, Inc. has entered into an agreement to produce Trubion Pharmaceuticals’ TRU-016, a novel protein for the treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Terms of the manufacturing agreement were not disclosed.

“We are pleased that Trubion chose Laureate Pharma to manufacture TRU-016 for preclinical and clinical testing and we look forward to working with them on this novel product,” said Robert J. Broeze, Ph.D., president and chief executive officer of Laureate Pharma.

Trubion’s TRU-016 targets CD37, an antigen present on B cells, for the treatment of NHL and CLL. Subject to completion of preclinical testing, the company expects to file an IND for TRU-016 in the second half of this year. Trubion currently retains all development and commercialization rights for the TRU-016 program.